A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS

被引：0

作者：

Puduvalli, Vinay ^{[1
]}

Wu, Jing ^{[2
]}

Yuan, Ying ^{[3
]}

Armstrong, Terri ^{[2
]}

Wu, Jimin ^{[3
]}

Giglio, Pierre ^{[4
]}

Xu, Jihong ^{[1
]}

Colman, Howard ^{[5
,6
]}

Walbert, Tobias ^{[7
]}

Raizer, Jeffrey ^{[8
]}

Groves, Morris ^{[9
]}

Iwamoto, Fabio ^{[10
]}

Tran, David ^{[11
]}

Avgeropoulos, Nicholas ^{[12
]}

Paleologos, Nina ^{[13
]}

Fink, Karen ^{[14
]}

Peereboom, David ^{[15
]}

Chamberlain, Marc ^{[16
]}

Merrell, Ryan ^{[17
]}

Penas-Prado, Marta ^{[3
]}

Yung, W. K. Alfred ^{[18
]}

Gilbert, Mark ^{[2
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[2] NCI, Neurooncol Branch, CCR, NIH, Bethesda, MD 20892 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Ohio State Univ, Columbus, OH 43210 USA

[5] Univ Utah, Dept Neurosurg, Huntsman Canc Inst, Salt Lake City, UT USA

[6] Univ Utah, Clin Neurosci Ctr, Salt Lake City, UT USA

[7] Henry Ford Hosp, Detroit, MI 48202 USA

[8] Northwestern Univ, Chicago, IL 60611 USA

[9] Texas Oncol Austin Brain Tumor Ctr, Austin, TX USA

[10] Columbia Univ, New York, NY USA

[11] Univ Florida, Gainesville, FL USA

[12] Univ Florida, Orlando, FL USA

[13] Advocate Hlth Care, Chicago, IL USA

[14] Baylor Univ, Dallas, TX USA

[15] Cleveland Clin, Cleveland, OH 44106 USA

[16] Univ Washington, Seattle, WA 98195 USA

[17] Northshore Univ, Evanston, IL USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA

来源：

NEURO-ONCOLOGY | 2018年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ACTR-13

引用

页码：13 / 13

页数：1

共 50 条

[31] PHASE I/II TRIAL OF RADIOSURGERY PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT/PROGRESSIVE GLIOBLASTOMA - INITIAL REPORT
Mohammadi, Alireza Mohammad
Chao, Samuel T.
Peereboom, David M.
Barnett, Gene H.
Suh, John H.
Brewer, Cathy
Vogelbaum, Michael A.
NEURO-ONCOLOGY, 2012, 14 : 103 - 104
[32] Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results
Reardon, D.
Desjardins, A.
Vredenburgh, J. J.
Gururangan, S.
Peters, K. B.
Norfleet, J. A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[33] A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)
Ahluwalia, Manmeet
Fallah, Jaleh
Peereboom, David
Schilero, Cathy
Ali, Assad
Forst, Deborah
Wong, Eric
Wen, Patrick
Reardon, David
NEURO-ONCOLOGY, 2019, 21 : 220 - 220
[34] A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET)
Field, Kathryn Maree
Simes, John
Wheeler, Helen
Hovey, Elizabeth J.
Nowak, Anna K.
Cher, Lawrence
Brown, Chris
Livingstone, Ann
Sawkins, Kate
Rosenthal, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[35] Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology).
Soffietti, R.
Trevisan, E.
Ruda, R.
Bertero, L.
Bosa, C.
Fabrini, M. G.
Lolli, I.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[36] PHASE II TRIAL OF BEVACIZUMAB WITH FOTEMUSTINE IN RECURRENT GLIOBLASTOMA: FINAL RESULTS OF A MULTICENTER STUDY OF AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY)
Soffietti, Riccardo
Trevisan, Elisa
Ruda, Roberta
Bertero, Luca
Bosa, Chiara
Fabrini, Maria Grazia
Lolli, Ivan
NEURO-ONCOLOGY, 2011, 13 : 56 - 57
[37] RANDOMIZED PHASE II OPEN-LABEL STUDY OF NIVOLUMAB PLUS STANDARD-DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW-DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM): FINAL REPORT
Ahluwalia, Manmeet
Khosla, Atulya
Rauf, Yasmeen
Peereboom, David
Wen, Patrick Y.
Reardon, David A.
NEURO-ONCOLOGY, 2022, 24 : 64 - 64
[38] Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.
Bota, D. A.
Eroglu, Z.
Reardon, D. A.
Fu, B. D.
Norfleet, J.
Desjardins, A.
Linskey, M. E.
Peters, K.
Friedman, H. S.
Vredenburgh, J. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[39] Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Taal, Walter
Oosterkamp, Hendrika M.
Walenkamp, Annemiek M. E.
Dubbink, Hendrikus J.
Beerepoot, Laurens V.
Hanse, Monique C. J.
Buter, Jan
Honkoop, Aafke H.
Boerman, Dolf
de Vos, Filip Y. F.
Dinjens, Winand N. M.
Enting, Roelien H.
Taphoorn, Martin J. B.
van den Berkmortel, Franchette W. P. J.
Jansen, Rob L. H.
Brandsma, Dieta
Bromberg, Jacoline E. C.
van Heuvel, Irene
Vernhout, Rene M.
van der Holt, Bronno
van den Bent, Martin J.
LANCET ONCOLOGY, 2014, 15 (09): : 943 - 953
[40] Letter to the Editor: Commentary on "Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma"
Tini, Paolo
JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (41)

← 1 2 3 4 5 →